Clinical Trial Detail

NCT ID NCT02335814
Title First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Flexus Biosciences, Inc.
Indications

acute myeloid leukemia

Therapies

FLX925

Age Groups: adult

Additional content available in CKB BOOST